- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05077423
A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1, Open-label, Dose-escalation Trial of CD33xCD3 Bispecific Antibody in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
Study Overview
Detailed Description
This is an open label, first in human dose escalation trial in pediatric patients with relapsed or refractory acute myeloid leukemia to assess the safety and tolerability of increasing doses of CD33xCD3 BsAb administered subcutaneously.
A modified Bayesian Optimal Interval Design (mBOIN) design will be applied. The trial will start with accelerated titration using single patient cohorts until one grade ≥2 AE not clearly associated to underlying disease, thereafter the trial will continue with mBOIN titration.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Children's of Alabama/University of Alabama at Birmingham
-
-
California
-
Orange, California, United States, 92868
- Children's Hospital of Orange County
-
San Francisco, California, United States, 94158
- UCSF Benioff Children's Hospital
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Children's National Hospital
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202-5225
- Riley Hospital for Children - Indiana University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota/Masonic Cancer Center
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, United States, 15224
- UPMC Children's Hospital of Pittsburgh
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- St Jude Children's Research Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Signed informed consent from legal guardian(s), patient and/or child obtained in accordance with local regulations. Pediatric patients must provide assent as required by local regulations
- Age ≥2 years, and ≤21 years, and a minimum body weight of ≥11 kg
- Histologically confirmed relapsed or refractory AML (except acute promyelocytic leukemia) with no therapeutic options that may provide clinical benefit. Disease burden ≥5.0% in the bone marrow meets definition for enrollment.
- Karnofsky performance status ≥50 for ≥16 years / Lansky performance status ≥50 for <16 years
- White blood cells (WBC) ≤25 x 109/L (may receive hydroxyurea to bring WBC count down prior to first dose of CD33xCD3 BsAb and during Cycle 1 or low dose cytarabine up to 48 h prior to first dose of CD33xCD3 BsAb)
Central Nervous System (CNS) disease as per Children's Oncology Group
- Patients must have the status of CNS1 and no clinical signs or neurologic symptoms suggestive of CNS leukemia, such as cranial palsy
- Patients with CNS3 or CNS2 status may receive antecedent intrathecal chemotherapy to achieve CNS1 status prior to trial entry
- Patients with a history of CNS chloromatous disease are required to have no radiographic evidence of disease prior to enrollment
- Has acceptable liver and kidney laboratory values
- Patient must have recovered from acute toxic effects of prior anti-cancer therapies prior to first dose of CD33xCD3 BsAb
Exclusion Criteria:
- History of uncontrolled seizure. If on anti-convulsant and/or seizures are well controlled as per treating physician enrollment is acceptable
- Acute promyelocytic leukemia with PML-RARA genetic abnormality according to WHO classification or t(15;17)
- Isolated extramedullary AML
- Clinically significant graft-versus-host disease (GvHD) secondary to prior allogeneic transplantation. No immunosuppressive therapy for ≥14 days prior to first dose, except for topical corticosteroids for minor rash (<5% of BSA) or adrenal replacement therapy
- Patient known to have one of the following genetic syndromes: Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Nijmegen breakage syndrome, Kostmann syndrome, Shwachman Diamond syndrome or any known bone marrow failure syndrome where increased risk for toxicity may be expected as judged by the Investigator
Treatment with another investigational agent under the following conditions:
- Within two weeks (four weeks for biologics) before first administration of CD33xCD3 BsAb; or
- Patient has persistent toxicities from prior anti-leukemic therapies which are determined to be relevant by the Investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Subcutaneous administration of CD33*CD3 BsAb up to 12 cycles
|
CD33xCD3 is a bispecific monoclonal antibody, which specifically targets CD33 on the AML blasts and CD3 on the T cells
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of dose limiting toxicities (DLTs)
Time Frame: 28 days
|
Occurrence of DLTs during a DLT period .
|
28 days
|
Occurrence of Adverse Events
Time Frame: 52 weeks
|
Occurrence of Adverse Events during the trial
|
52 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jessica Pollard, MD, Dana-Farber Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 801
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on AML, Childhood
-
Therapeutic Advances in Childhood Leukemia ConsortiumBristol-Myers SquibbActive, not recruitingAML, ChildhoodUnited States
-
Elucida OncologyTherapeutic Advances in Childhood Leukemia and Lymphoma (TACL)WithdrawnAcute Myeloid Leukemia | AML, Childhood | Relapsed Pediatric AML | Refractory Pediatric AML
-
Children's Hospital of Soochow UniversityRecruitingAcute Myeloid Leukemia | AML, ChildhoodChina
-
Washington University School of MedicineThe Leukemia and Lymphoma Society; Rising Tide Foundation; St. Louis Children...Not yet recruitingAcute Myeloid Leukemia | Aml | AML, Childhood | Acute Myeloid Leukemia, PediatricUnited States
-
Emory UniversityTerminated
-
H Scott BoswellTakedaTerminatedAML | AML, AdultUnited States
-
Technische Universität DresdenAbbVieActive, not recruitingRelapsed Adult AML | Refractory AMLGermany
-
St. Jude Children's Research HospitalNot yet recruitingLymphoma | Hematologic Malignancy | MDS | AML, Childhood | ALL, ChildhoodUnited States
-
Children's Hospital of Soochow UniversityRecruitingAML, Childhood | C-KIT Mutation | Refractory AML | Relapse/Recurrence | Core Binding Factor Acute Myeloid LeukemiaChina
-
Carbiogene Therapeutics Co. Ltd.Zhejiang Provincial People's HospitalRecruiting
Clinical Trials on CD33*CD3 BsAb
-
Binhui Biopharmaceutical Co., Ltd.Recruiting
-
Molecular Partners AGRecruitingLeukemia | Acute | Relapsed | MyeloidNetherlands, France, Lithuania, Switzerland
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Jiangsu Alphamab Biopharmaceuticals Co., LtdSunshine Lake Pharma Co., Ltd.Terminated
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.The First People's Hospital of Hefei; Hefei Binhu HospitalUnknownAcute Myeloid Leukemia | Acute Myelogenous Leukemia | Acute Myeloid Leukemia With Maturation | Acute Myeloid Leukemia Without Maturation | ANLLChina
-
Southwest Hospital, ChinaUnknown
-
Chinese PLA General HospitalUnknownRelapsed Adult Myeloid Leukemia | Chemotherapy Refractory Adult Myeloid LeukemiaChina
-
Guangzhou Bio-gene Technology Co., LtdWithdrawnAcute Myeloid LeukemiaChina
-
Zhejiang UniversityNot yet recruiting
-
iCell Gene TherapeuticsThe General Hospital of Western Theater Command; Peking University Shenzhen... and other collaboratorsRecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Hematologic Malignancy | Myeloproliferative NeoplasmChina